Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.

By M. Schlumberger, M. Tahara, L. Wirth, B. Robinson, M. Brose, R. Elisei, M. Habra, K. Newbold, M. Shah, A. Hoff and 9 more. New England Journal of Medicine, 2015

1,766 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/26b916f5e0a52dc3fae776c9e043429a2a9c3e0a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Sebastiano Filetti
2. Masatoshi Kudo
3. Joong-Won Park
4. S. Qin
5. C. Durante
6. A. Cheng
7. Richard S. Finn
8. D. Hartl

Citations in the corpus

• Trends in thyroid cancer incidence and mortality in the United States, 1974–2013 (2017, background): “advanced, iodine-resistant differentiated thyroid cancer including PTC, but neither has been shown yet to afford a survival advantage, likely due to the indolent natural history of thedisease.(37,38)Clinical trials tooptimize thedevelopmentand use of novel systemic therapies are necessary.”
• Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2019, background): “Both drugs have been investigated in two large, randomised phase III trials (sorafenib in DECISION [96], lenvatinib in SELECT [97]).”
• Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. (2018, result): “Lenvatinib monotherapy was approved for the treatment 110 of radioiodine-refractory differentiated thyroid cancer.(16) Lenvatinib and everolimus were approved as a 111 combined treatment for advanced renal cell carcinoma following 1 prior anti-angiogenic therapy.”